Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genetically Modified L3,7 and L2 Lipooligosaccharides from Neisseria meningitidis Serogroup B Confer a Broad Cross-Bactericidal Response

17 Mar 2009

Abstract excerpt

Currently available Neisseria meningitidis serogroup B (MenB) vaccines are based on outer membrane vesicles (OMVs) that are obtained from wild-type strains. They are purified with the aim of decreasing the lipooligosaccharide (LOS) content and hence reduce the reactogenicity of the vaccine even though LOS is a potential protective antigen. In <2-year-old children, these MenB vaccines confer protection only...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Bacterial Infections and Vaccines
Share to Escherichia coli research studies
Share to Pneumonia and Respiratory Infections

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 19289516
DOI: 10.1128/iai.01108-08

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 16 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genetically Modified L3,7 and L2 Lipooligosaccharides from Neisseria meningitidis Serogroup B Confer a Broad Cross-Bactericidal ResponsePMID 19289516Read ↗

Next-generation outer membrane vesicle vaccines against Neisseria meningitidis based on nontoxic LPS mutants.Semantic proximity Read ↗

Improved OMV vaccine against Neisseria meningitidis using genetically engineered strains and a detergent-free purification process.Semantic proximity Read ↗

Adjuvant effects elicited by novel oligosaccharide variants of detoxified meningococcal lipopolysaccharides on Neisseria meningitidis recombinant PorA protein: a comparison in mice.Semantic proximity Read ↗

Characterization of native outer membrane vesicles from lpxL mutant strains of Neisseria meningitidis for use in parenteral vaccination.Semantic proximity Read ↗

Novel approaches to Neisseria meningitidis vaccine designSemantic proximity Read ↗

Strategies for Development of Universal Vaccines Against Meningococcal Serogroup B DiseaseSemantic proximity Read ↗

Protective Antibody Responses Elicited by a Meningococcal Outer Membrane Vesicle Vaccine with Overexpressed Genome‐Derived Neisserial Antigen 1870Semantic proximity Read ↗

The Development of a Vaccine Against Meningococcus B Using Reverse VaccinologySemantic proximity Read ↗

Lipooligosaccharide structure contributes to multiple steps in the virulence of Neisseria meningitidis.Semantic proximity Read ↗

How the Knowledge of Interactions between Meningococcus and the Human Immune System Has Been Used to Prepare Effective<i>Neisseria meningitidis</i>VaccinesSemantic proximity Read ↗

OpcA and PorB are novel bactericidal antigens of the 4CMenB vaccine in mice and humansSemantic proximity Read ↗

Deletion of major porins from meningococcal outer membrane vesicle vaccines enhances reactivity against heterologous serogroup B Neisseria meningitidis strainsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.